[The effects of 1-(4-cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane (talinolol, Cordanum, 02-115), practolol and propranolol on the lipid content of the rat serum].
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D002784:Cholesterol / Q000097:blood; D005230:Fatty Acids, Nonesterified / Q000097:blood; D007274:Injections, Intraperitoneal; D007545:Isoproterenol / Q000037:antagonists & inhibitors; D008055:Lipids / Q000097:blood*; D008297:Male; D010743:Phospholipids / Q000097:blood; D011217:Practolol / Q000494:pharmacology*; D011412:Propanolamines / Q000494:pharmacology*; D011433:Propranolol / Q000494:pharmacology*; D051381:Rats
D000319:Adrenergic beta-Antagonists; D005230:Fatty Acids, Nonesterified; D008055:Lipids; D010743:Phospholipids; D011412:Propanolamines; D002784:Cholesterol; D011433:Propranolol; D007545:Isoproterenol; D011217:Practolol
Wirkung von 1-[4-Cyclohexylureidophenoxyl-2-hydroxy-3-tert.-butylaminopropan (Talinolol, Cordanum, 02-115), Practolol und Propranolol auf den Lipidgehalt des Serums der Ratte